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Olfactory testing in consecutive patients
referred with suspected dementia
Ib Thrane Christensen1, Elna-Marie Larsson2, Ida E. Holm3, Ole B.F. Nielsen1 and Stig Andersen1,4*
Abstract
Background: Alzheimer’s disease (AD) is the most common cause of dementia and early and accurate diagnosis is
important. Olfactory dysfunction is an early sign of AD. The contribution by test of olfactory function has been
surveyed in AD vs a line of conditions but remains to be settled in the workup of unselected patients referred with
suspected dementia.
Methods: We performed a two-step investigation: first, a comparative study of healthy controls and probable AD
patients to test the applicability of the chosen scents (cuisine study); second, a study of consecutive patients
referred to our geriatric outpatient clinic for suspected dementia with the investigating personnel blinded to the
results of the Olfactory Test (blinded study).
Results: The sum of scents detected discriminated patients with probable AD from controls in the cuisine study
(n = 40; p < 0.001; area under ROC curve 0.94). In the blinded study (n = 50) the diagnosis was probable AD in 48%,
minimal cognitive impairment in 24%, vascular dementia in 8%, alcohol induced impairment in 12%, depression in
4%, and Parkinson’s disease and Lewy body dementia in 2%. Area under the ROC-curve was 0.67. The odds ratio for
probable AD with 2+ smell errors was 12 (95%-CI: 1.3–101; p = 0.026 (reference 0–1 smell errors)) age adjusted.
None in the AD group had zero smell errors (Negative Predictive Value 100%).
Conclusion: Olfactory testing may support to dismiss the diagnosis of probable AD in the workup of a mixed
group of patients referred with cognitive impairment. Still, it had a low sensitivity for probable AD.
Keywords: Dementia, Alzheimer’s disease, Cognitive impairment, Olfactory dysfunction, Pocket smell test, Blinded
study, Cuisine study
Background
Alzheimer’s disease (AD) is the most common form of
dementia [1]. It is characterized clinically by memory
deficit followed by cognitive decline [1, 2]. Early diagno-
sis is important to prompt treatment and measures to
aid patient and family caregivers [3] who may require
support in their coping and understanding [4]. Hence,
the quest for diagnostic precision for AD is advancing to
include advanced genetic biomarkers in blood [5],
markers in cerebrospinal fluid [6], and clinical tests such
as recognition of emotions in facial expressions [7] to
support early and accurate diagnosis of probable AD.
Olfactory information is processed in the medial tem-
poral lobe and olfactory dysfunction relate to the extent
of neuropathological changes in neurodegenerative
diseases [8]. Olfactory dysfunction occurs in old age [9],
but the age-related decline in olfactory function is accel-
erated in patients with AD and Parkinson’s disease (PD)
[10, 11]. The ability to identify different odours is altered
in the early stages of AD [12] and testing of olfactory
function has been suggested as a diagnostic tool for AD
from the early stages [12–15]. Furthermore, studies sup-
port the use of scent identification tests to aid the
distinction between AD and depression [16] and vascular
dementia [17].
Several commercially available tests of olfaction have
been developed. They vary in number and quality of
smells adjusted to cuisine and cultural differences
[15, 18–20]. While the US population is familiar with
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root beer, pickles and gingerbread Europeans are not.
Hence, different odour identification tests have been
developed for use in the US [15, 19, 20] and in Eur-
ope [18, 20].
This led us to first validate the ability of six chosen
scents to separate patients with probable AD from healthy
controls in a simple and quick scratch-and-sniff test. Sub-
sequently, we applied this technique in a convenience
study to test the usefulness of the test to discriminate
probable AD from non-AD among consecutive patients
referred with cognitive decline when the health care pro-
fessional involved in the diagnostic work-up was blinded
to the results of the olfactory test.
Methods
The study consisted of two parts. First, we conducted a
cuisine pilot-study to validate the ability of selected
scents to be detected by patients with AD and by healthy
controls in Denmark. Second, we conducted a study of
patients referred consecutively to our geriatric out-
patient clinic for evaluation of cognitive decline with the
clinicians blinded to the olfactory testing results.
Cuisine study
Participants were recruited from the outpatient clinic at
the Geriatric Department. The controls were volunteers
from the local elderly community and healthy partners
of the patients, and they were matched by gender.
Exclusion criteria included a history of nose-throat
pathology with increasing sinusitis or chronic sinusitis, a
flue condition, previous brain trauma, concussion of the
brain with unconsciousness, and cerebral surgery.
Blinded study
Participants were consecutive patients referred to the
geriatric outpatient clinic at Aalborg University Hospital
for evaluation of cognitive decline. Inclusion terminated
at fifty patients. Exclusion criteria were similar to those
applied in the cuisine study.
Test of olfaction
We used a scent test with a scratch and sniff technique. It
encompassed pads that release odours when scratched.
The scent test was a Pocket Smell Test (PST) (Sensonic
P.O.B. 112, Hadom High, New Jersey, US). Each PST in-
cluded three different scents. Two different PSTs were used
and each patient was exposed to six different scents. We
chose PSTs with six different scents that had an inter-
national applicability (citrus, lilac, smoke, peanut, menthol,
paint thinner).
Subjects were kept in a scent free room for at least
15 min prior to the test.
The test was appropriate for self-administration. How-
ever, short term memory is limited in these patients and a
study-nurse scratched the pads and read the choices aloud
in order to reduce cognitive load and to standardize
administration as the focus was on providing the best
environment for the patients to do the test. In the case of
uncertainty the test was repeated and the patient was
given one additional opportunity to complete the test.
Each smell was evaluated in two steps. First step: is
there a smell yes/no. If no, then the participant did not
pass. Second step consisted of four choices of which one
matched the odour. The participant passed only if the
correct smell was reported. Declining any of the four
smells was recorded as not passing the test. Thus, we
did not apply forced choice.
The result of the olfactory test (OT) was blinded to
the examining doctor and nurse in the blinded study. A
study nurse performed the test prior to the additional
evaluation and this nurse was not involved in the subse-
quent work-up of the patient. The test results were kept
unveiled until termination of the study.
Clinical evaluation
All patients underwent clinical evaluation that included
height, weight, routine laboratory tests, ECG, Folstein
mini-mental state evaluation (MMSE test), geriatric de-
pression scale (GDS), CT-scan of the brain, and history
taking to evaluate the cognitive deficit. MMSE and GDS
were performed at the first visit to the outpatient clinic.
Final evaluation that led to the diagnosis was performed
at a follow-up visit. As the study was set up to reflect
the clinical practice patients were diagnosed with prob-
able AD according to the ICD-10 criteria supported by
the criteria set up by Goutie [21]. Diagnosis was made
without knowledge of OT results.
All patients were examined with CT of the brain with-
out contrast injection with a 5–10 mm slice thickness.
An experienced neuro-radiologist (EML) evaluated all
CT images and recorded cerebral infarctions and cortical
atrophy prior to the clinical and biochemical evaluation.
Ethical approval was obtained from the Ethics Commit-
tee for Viborg and Nordjyllands Counties (VN-20060056)
before commencement of the study and all participants
gave written informed consent.
Statistical analysis
Mean values were compared using Mann-Whitney U
test and correlations were tested using Spearman’s rho.
Proportions were compared using chi-squared test or
Fischer exact test if groups were small. ROC curve was
produced and the accuracy of the test was interpreted as
excellent, good, fair, poor, and fail with an area under
the curve (AUC) of >0.9, 0.8–0.9, 0.7–0.8, 0.6–0.7 and
0.5–0.6 respectively. AD was entered as dependent
variable in logistic regression with age and OT results
entered as explanatory variables. Data were processed
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and analysed using Corel Quattro Pro 8 and the statis-
tical package for the social sciences version 13.0 (SPSS
Inc., Chicago, Illinois). A p-value of less than 0.05 was
considered significant.
Results
The cuisine study consisted of 20 patients with probable
AD and 20 healthy controls with similar gender distribu-
tion (Table 1). Patients were 5.5 years older than con-
trols. The blinded study included 50 patients with
suspected dementia. This group displayed equal gender
distribution between those diagnosed with AD compared
to those with cognitive impairment of other origin (non-
AD) (Table 1). The patients with AD were older than
non-AD patients. Two AD patients had no scent regis-
tration. All other AD patients confirmed some scent
registration when exposed.
Cuisine study
AD patients scored a markedly higher number of errors
on the OT compared to controls in the pilot study with
an area under the ROC curve of 0.94 (Fig. 1). An average
of 10.5 AD patients detected correct smells compared to
16.8 healthy controls (p = 0.005). All individual scents
differed between AD and non-AD except lilac (Table 2).
Blinded study
The detection of one single scent differed clearly be-
tween AD and non-AD patients while all individual
scents displayed a slightly higher number of errors in
AD patients compared to non-AD patients (Table 2).
The sum of scent errors differed between AD patients
and those with other causes of cognitive impairment
(p = 0.024) (Table 3). The contribution by OT to the
classification as probable AD and non-AD is illustrated
in Fig. 2 (area under the ROC curve 0.67). The test
showed the higher accuracy at the extremes and the
lower accuracy at the central area.
None of the AD patients detected all scents correctly
(Table 4, p = 0.045) and none without scent errors had
AD (Table 4, p = 0.10). The odds ratio for AD in
patients with 2 or more smell errors was 12 (95%-CI:
1.3–101; p = 0.026) after adjusting for age (Table 5).
Positive predictive value for AD was 100% with max-
imum number of smell errors in this population while
negative predictive value for AD was 100% with no smell
errors in this population (Table 5).
OT associated with MMSE score (Spearmann’s rho −0.42,
p = 0.002) and MMSE score associated with OT in non-
AD patients (p = 0.029) while not in AD patients (ns). The
number of scent errors differed with gender in non-AD pa-
tients (median in men/women 1.0/3.0; p = 0.022) while not
in AD-patients (men/women 4.0/3.0; p = 0.71). Geriatric
Depression Score may be lower in AD patients than in
non-AD patients (p = 0.11; Table 3). AD and non-AD
patients did not differ markedly in the number of subjects
Table 1 Participant characteristics in a study comparing
patients with probable Alzheimer’s disease (AD) and controls
(cuisine study) and a study of patients referred for workup of
suspected dementia blinded to the results of olfactory testing
(blinded study)
Cuisine Study Blinded Study
AD Controls p-value AD not AD p-value
Gender
Men 7 7 ns* 12 13 ns*
Women 13 13 12 13
Age (mean)
(years)
80.9 75.4 0.001** 81.9 76.5 0.015**
(range) (72–88) (69–84) (67–91) (58–90)
*Chi-squared test
**Mann-Whitney U test
00. 0
52.0
05. 0
57.0
00. 1
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.9425
ROC, AD-prediktion - antal fejl (pilot-projektet)
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Fig. 1 ROC curve from the cuisine study on the sensitivity and
specificity of olfactory testing when comparing probable Alzheimer’s
disease with healthy controls
Table 2 Number of errors for each scent among controls,
Alzheimer’s disease (AD) and other causes of cognitive impairment
Cuisine Studya Blinded Studyb
ADc Controls p-valued ADc non-ADc p-valued
n (%) n (%) n (%) n (%)
Citrus 14 (70) 4 (20) <0.01 15 (62) 10 (38) ns
Lilac 10 (50) 9 (45) ns 15 (62) 15 (58) ns
Smoke 12 (60) 0 (0) <0.001 9 (37) 8 (31) ns
Peanut 12 (60) 5 (25) <0.05 13 (54) 10 (38) ns
Menthol 11 (55) 1 (5) <0.001 16 (67) 13 (50) ns
Paint thinner 12 (60) 0 (0) <0.001 18 (75) 8 (31) <0.01
aComparing patients with probable Alzheimer’s disease and helathy controls.
bstudy of consecutive patients referred for suspected dementiat with the
results of test of olfactory function blinded to the diagnosis
cAlzheimer’s disease
dChi-squared test or Fishers exact test when n < 5
ns p-value >0.05
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with cerebral infarctions (p = 0.47) or cerebral atrophy
(p = 0.15) (Table 3).
Cuisine and blinded study
All patients with probable AD had high numbers of
errors on OT and this did not differ between patients in
the blinded study and the cuisine study (59.2 vs. 59.7%, ns).
Patients with cognitive impairment of other cause than AD
had more errors on the OT than did the healthy controls
(41.0 vs 15.8%, p < 0.001).
Discussion
We made a two-step investigation. First, we validated
the applicability of a commercially available 6-item PST
with an international applicability in an elderly popula-
tion in Denmark. We found that five of the six scents
individually contributed markedly to the OT in making
a distinction between probable AD patients and healthy
controls, and the area under the ROC curve suggested
excellent distinction between the two groups. Second,
we tested the usefulness of this OT in a blinded study
among consecutive patients referred with suspected de-
mentia. The accuracy of the OT was poor in the blinded
study as evaluated from the area under the ROC curve.
Still, we found that the OT provided some contribution
to the diagnostic workup of patients with suspected
dementia in supporting to dismiss the diagnosis of prob-
able AD in the group with a single or no errors on the
OT. Interestingly, this was further supported by the fact
that all 46 patients with probable AD in both studies
had one or more errors in the six scents included in this
PST, and none of the non-AD patients or controls had
all scents incorrect.
Cognitive impairment is common in old age and AD is
the most frequent form of dementia. Early diagnosis of
Table 3 Findings among 50 consecutive patients referred for suspected dementia to the outpatient clinics at Department of Geriatric
Medicin, Aalborg University Hospital
n Age MMSE scorea GDSb Cerebral Cortical Olfactory teste
years infarctionsc atrophyd Errors
mean (range) mean (range) mean (range) n n mean (range)
Alzheimers disease 24 81.9 (67–91) 22.5 (11–29) 2.1 (0–7) 6 9 3.6 (1–6)
Not Alzheimers disease 26 76.5 (58–90) 24.0 (10–30) 3.5 (0–14) 9 4 2.5 (0–5)
Minimal cognitive impairment 12 81.3 (72–90) 24.4 (10–29) 2.7 (0–9) 5 2 2.0 (0–5)
Lewi body dementia 1 77.0 24.0 4.0 0 0 3.0
Vascular dementia 4 79.2 (73–84) 22.5 (13–27) 1.5 (1–2) 3 0 3.0 (1–4)
Parkinson’s disease 1 63.0 28.0 1 0 3.0
Depression 2 79.5 (79–80) 27.5 (25–30) 2.0 (0–4) 0 1 1.5 (0–3)
Alcohol induced impairment 6 66.2 (58–78) 22.5 (12–30) 4.8 (1–14) 0 1 3.2 (0–5)
aFolstein mini-mental state evaluation (MMSE test)
bGeriatric Depression Scale. Data missing for a patient with Parkinson’s disease
c > 3 mm on CT of the brain
dSulci widening grade 3
eNumber of incorrect answers of 6 possible in the Pocket Smell Test
Fig. 2 ROC curve to depict the sensitivity and specificity of olfactory
testing to detect probable Alzheimer’s disease in the blinded study
of consecutive patients referred to a geriatric outpatient clinic for
workup of suspected dementia
Table 4 Number of smell errors as detected in patients with
probable Alzheimers Diasease (AD) or non-AD patients in the
blinded study
AD non-AD
na na
Number of smell errors:
0 0 4
1 1 5
2 4 3
3 7 7
4 7 3
5 2 4
6 3 0
aNumber of patients
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probable AD is crucial to support intervention for the
benefit of patient and family [3, 4]. However, the path-
ology of AD may be present decades before a clinical diag-
nosis of dementia [2, 22]. Early changes in AD include
smell deficits [12] but smell deficits are seen in a number
of other neurodegenerative disorders [10]. Yet, a recent
functional MRI study in AD patients confirmed a degener-
ation of neural structures responsible for olfactory func-
tion [23]. This supports that a central component is
predominant in the damage to the smell pathways in AD
patients and that loss of smell is an early sign of AD [12]
that may be present before the diagnosis of probable AD.
It has been suggested that OT should be used in clinical
routine for early identification of progression of the
decline from mild cognitive deficits to probable AD
[12–15, 22]. We took a different view and studied its
applicability in a routine clinical setting of patients re-
ferred consecutively for suspected dementia.
Cognitive impairment may have several causes such as
depression, infection, and the use of multiple drugs. In
fact, one of our participants had a MMSE score of 10 at
the first visit but after tapering of morphine the cogni-
tive impairment decreased markedly and the patient
ended up with the diagnosis of MCI. Thus, the mean
MMSE score went up to 25.7 points for the MCI group
when testing only the remaining patients, of which the
scores ranged from 21 to 29.
Our data confirm previous findings that patients with
probable AD have a markedly reduced ability to
recognize scents [11–15, 18]. A study from Norway
found similar results to our cuisine study when testing
AD patients and healthy controls using the Brief Smell
Identification Test (B-SIT) with twelve different scents
[24]. The highly statistically significant results of our
cuisine study suggest that a lower number of scents will
suffice.
Test of olfactory function may face practical problems
such as stability of the scent. We chose a scratch and
sniff technique from the company Sensonic [19]. Tests
were available with different elements, and we chose two
PSTs that each included three scent pads. It has been
demonstrated that a single PST can aid a distinction
between AD and major depression [16, 17] and we used
two different PSTs to accommodate the number of tests
aimed for.
Patients in the blinded convenience study all had some
degree of cognitive impairment. We found limited specifi-
city of the OT in the workup of the group of patients with
mixed cause of cognitive impairment. Still, the difference in
the association between MMSE score and OT in AD versus
non-AD patients with cognitive impairment is consistent
with a difference in olfactory function between these pa-
tients. This was also seen with the gender difference in
scent detection between AD and non-AD patients. OT was
not sufficiently accurate to be used as a sole diagnostic tool
for diagnosis of probable AD, but six errors could be seen
as supporting probable AD with a positive predictive value
for AD of 100% in our data. Interestingly, taking the oppos-
ite view, the six-item OT may suggest dismissing the diag-
nosis of probable AD among those who had no errors in
our study as we found a negative predictive value of 100%
in this group. This is in keeping with three studies testing
smell among AD patients using the PST [25] and the
B-SIT [24, 26]. Hence, having no smell-error supports
dismissing the diagnosis of probable AD.
Odour identification depends on cultural and cuisine
areas [18, 24] and the relevance of odours may need val-
idation prior to implementing an OT. However, similar-
ities exist within cultural and geographical areas and the
distinct value in five of six individual scents seen in our
study suggests that these may be applicable to other
countries in northern Europe.
Table 5 Prediction of the diagnosis of Alzheimer’s disease in an out-patient population referred for evaluation of dementia (blinded study)
Alzheimers disease
Pa ORb 95-CI Pc ORc 95-CI PPV (%)f NPV (%)g
Number of smell errors
1+ (0 reference) 0.045 nad nad 52 100
2+ (0–1 reference) 0.011 12.2 1.4–105 0.026 11.6 1.3–101 58 90
3+ (0–2 reference) 0.059 3.3 0.9–11.4 0.078 3.3 0.9–12.1 58 71
4+ (0–3 reference) 0.093 2.7 0.8–8.8 0.055 3.5 1.0–12.6 63 61
5+ (0–4 reference) 0.62 1.4 0.3–6.2 0.73 1.3 0.3–6.6 56 54
6 (0–5 reference) 0.10 nae nae 100 55
aChi squared test, Fisher’s exact test if n < 5
bUnivariate logistic regression
cMultivariate model adjusted for age (<80y) and MMSE (<20)
dNot applicable: 4, all non-AD
eNot applicable: 3 reference, all AD
fPositive predictive value, %
gNegative predictive value, %
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Performance of the scent identification tests poses risk
of error. Adaptation and cross-adaptation may com-
promise the validity of the test and the intensity of the
scent exposure should not be too strong. Also, the ex-
posure should be short and it is important for the scent
quantity and quality to be standardised. These require-
ments were accommodated by the scratch-and-sniff
technique. Furthermore, there is a risk of adaptation
with an increase in the number of smells tested and we
chose to use only six smells. This was supported by an
impression of a decreasing focus on the smell test with
increasing number of tests. The use of a brief test was
further justified by the fact that patients with dementia
have a limited window of short-term memory. This fur-
ther encouraged the procedure of having the study nurse
scratch and read aloud the four possible choices. Finally,
we kept the subjects in a scent neutral area for at least
15 min before scent exposure to minimise interference
with other scents and adaptation to support the validity
of our findings.
Forced choice of odour identification has been used
[19]. This causes one in four answers to be correct due
to chance. Patients who declined to guess odour com-
prised a group that performed similarly to the function-
ally anosmic group in the study by Damholdt [27]. Thus,
we chose not to use forced choice but rather categorized
the test results in these patients as ‘fail’. This occurred in
two AD patients. Also, some patients were in doubt and
the scratch, sniff and read aloud procedure was repeated.
A continued recognition of a scent was common in
these patients even though they were not able to name it
or identify it among the four possibilities given.
The ability to recognize scents is stabile from
around the age of 20 years to between 55 and 60 years
of age. Thereafter, the ability to recognize scent is
gradually reduced [8, 9, 25]. Hence, we adjusted for
age in our analysis.
Conclusions
Patients with probable AD with early olfactory impair-
ment make up a considerable proportion of patients
referred for evaluation of suspected dementia. Hence, a
brief, simple, convenient, and cheap test of olfactory
impairment is warranted. These characteristics apply to
the PST that has been shown here to add information in
the workup of a group of patients referred with cognitive
impairment. Its simplicity supports its use in routine
clinical practice. The results suggest that test of olfactory
function has the potential to dismiss the diagnosis of
probable AD. Finally, the difference in accuracy between
the cuisine study and the blinded study emphasise the
importance of putting a clinical test to the test in the
clinical setting intended for its use.
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